CN110974777B - An injectable hydrogel after craniocerebral trauma with responsive release and nutritive neural function - Google Patents
An injectable hydrogel after craniocerebral trauma with responsive release and nutritive neural function Download PDFInfo
- Publication number
- CN110974777B CN110974777B CN201910274328.5A CN201910274328A CN110974777B CN 110974777 B CN110974777 B CN 110974777B CN 201910274328 A CN201910274328 A CN 201910274328A CN 110974777 B CN110974777 B CN 110974777B
- Authority
- CN
- China
- Prior art keywords
- craniocerebral trauma
- injectable hydrogel
- hydrogel
- trauma
- pps
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010019196 Head injury Diseases 0.000 title claims abstract description 67
- 239000000017 hydrogel Substances 0.000 title claims abstract description 66
- 230000001537 neural effect Effects 0.000 title 1
- 230000000050 nutritive effect Effects 0.000 title 1
- 230000006870 function Effects 0.000 claims abstract description 24
- IQUCNXSZNHPPML-UHFFFAOYSA-N 2-chloro-n-[(4-chlorophenyl)-phenylmethyl]acetamide Chemical compound C=1C=C(Cl)C=CC=1C(NC(=O)CCl)C1=CC=CC=C1 IQUCNXSZNHPPML-UHFFFAOYSA-N 0.000 claims abstract description 23
- 210000005036 nerve Anatomy 0.000 claims abstract description 22
- 230000002980 postoperative effect Effects 0.000 claims abstract description 15
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims abstract description 5
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims abstract description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 5
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 5
- 239000001301 oxygen Substances 0.000 claims abstract description 5
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 5
- 238000000354 decomposition reaction Methods 0.000 claims abstract description 3
- 229940109262 curcumin Drugs 0.000 claims description 21
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 18
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 235000012754 curcumin Nutrition 0.000 claims description 9
- 239000004148 curcumin Substances 0.000 claims description 9
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 5
- 239000012046 mixed solvent Substances 0.000 claims description 5
- 238000001338 self-assembly Methods 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 abstract description 10
- 239000003814 drug Substances 0.000 abstract description 10
- 230000004044 response Effects 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 7
- 208000014674 injury Diseases 0.000 abstract description 7
- 238000002360 preparation method Methods 0.000 abstract description 7
- 206010052428 Wound Diseases 0.000 abstract description 6
- 206010061218 Inflammation Diseases 0.000 abstract description 4
- 230000008499 blood brain barrier function Effects 0.000 abstract description 4
- 210000001218 blood-brain barrier Anatomy 0.000 abstract description 4
- 230000015556 catabolic process Effects 0.000 abstract description 4
- 238000006731 degradation reaction Methods 0.000 abstract description 4
- 238000002347 injection Methods 0.000 abstract description 4
- 239000007924 injection Substances 0.000 abstract description 4
- 230000002490 cerebral effect Effects 0.000 abstract description 3
- 230000008733 trauma Effects 0.000 abstract description 3
- 230000009977 dual effect Effects 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 238000011160 research Methods 0.000 abstract description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 abstract 1
- 102000007072 Nerve Growth Factors Human genes 0.000 abstract 1
- 230000017531 blood circulation Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 239000004734 Polyphenylene sulfide Substances 0.000 description 21
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 10
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- MBNVSWHUJDDZRH-UHFFFAOYSA-N 2-methylthiirane Chemical compound CC1CS1 MBNVSWHUJDDZRH-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- QSECPQCFCWVBKM-UHFFFAOYSA-N 2-iodoethanol Chemical compound OCCI QSECPQCFCWVBKM-UHFFFAOYSA-N 0.000 description 4
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 4
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 4
- 102000000424 Matrix Metalloproteinase 2 Human genes 0.000 description 4
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 229920000069 polyphenylene sulfide Polymers 0.000 description 4
- 230000001228 trophic effect Effects 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- WQAQPCDUOCURKW-UHFFFAOYSA-N butanethiol Chemical compound CCCCS WQAQPCDUOCURKW-UHFFFAOYSA-N 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229940123457 Free radical scavenger Drugs 0.000 description 2
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 2
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 2
- 102000008730 Nestin Human genes 0.000 description 2
- 108010088225 Nestin Proteins 0.000 description 2
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 2
- 238000003125 immunofluorescent labeling Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 2
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 210000005055 nestin Anatomy 0.000 description 2
- 230000003959 neuroinflammation Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- GXFZCDMWGMFGFL-KKXMJGKMSA-N (+)-Tubocurarine chloride hydrochloride Chemical compound [Cl-].[Cl-].C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CC[NH+]3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 GXFZCDMWGMFGFL-KKXMJGKMSA-N 0.000 description 1
- -1 200 μ L Substances 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- 239000008709 Curare Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000272186 Falco columbarius Species 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000008763 Neurofilament Proteins Human genes 0.000 description 1
- 108010088373 Neurofilament Proteins Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241001279009 Strychnos toxifera Species 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001198 high resolution scanning electron microscopy Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003534 oscillatory effect Effects 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- RBKASMJPSJDQKY-RBFSKHHSSA-N tirilazad Chemical compound O=C([C@@H]1[C@@]2(C)CC=C3[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)CN(CC1)CCN1C(N=1)=CC(N2CCCC2)=NC=1N1CCCC1 RBKASMJPSJDQKY-RBFSKHHSSA-N 0.000 description 1
- 229960005155 tirilazad Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JABYJIQOLGWMQW-UHFFFAOYSA-N undec-4-ene Chemical compound CCCCCCC=CCCC JABYJIQOLGWMQW-UHFFFAOYSA-N 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/795—Polymers containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a preparation method of an injectable hydrogel with the functions of responding release and nourishing nerves after craniocerebral trauma operation. The research carries the PPS with active oxygen phase response by hydrophilic and hydrophobic effects on triglycerol monostearate (TGMS) which can be self-assembled into injectable hydrogel and matrix metalloproteinase response decomposition after craniocerebral trauma operation120-OH and neurotrophin; the injection is locally injected at the postoperative part of the cerebral trauma to achieve the effects of quick response and release and play the roles of anti-inflammation and nourishing nerves; through hydrogel injection administration, the blood circulation degradation of the whole body and the influence of a blood brain barrier are avoided, and the specific microenvironment for responding to the wound is achieved, and the medicine is responded and released layer by layer to further play the dual functions of resisting inflammation and nourishing nerves. Has clinical application and practical therapeutic significance.
Description
Technical Field
The invention relates to an injectable hydrogel with functions of response release and nerve nutrition after craniocerebral trauma operation, belonging to the field of preparation of craniocerebral trauma medicaments.
Background
Craniocerebral Trauma (TBI) has become a serious public health problem worldwide due to its high incidence, mortality and disability rate. Although the understanding of the pathogenesis of craniocerebral injury is continuously deepened, and the treatment of patients with craniocerebral trauma is obviously improved along with the continuous increase of new medicines and the continuous application of new technologies, in the process of treating TBI patients, the prominent problem is how to resist the limited or diffuse encephaledema after injury and the deficiency problem of the nerve function after injury. Therefore, it is very important to develop safe and reliable brain protection drugs.
The free radical scavenger is a substance effective in resisting neuroinflammation, and has the function of specifically depleting Reactive Oxygen Species (ROS) mediators in inflammatory tissues and playing a role in blocking inflammatory reaction. Both Tirilazad and superoxide dismutase have been used as free radical scavengers, but due to intravenous administration and the blood-brain barrier effect, sufficient concentrations in brain tissue have not been achieved, and the prognosis improvement for patients has not been achieved to the desired effect, leading to experimental failure. Curcumin as a multi-class compound extracted from plants can effectively regulate the differentiation of neural stem cells. Its extremely low solubility in water, and the associated unstable nature, extremely low bioavailability, limits its use as a neuroprotective agent. Research into increasing drug concentrations in brain tissue in the wound area has become a major challenge in the preparation of such drug delivery systems.
Disclosure of Invention
In order to overcome the defects of lack of craniocerebral trauma medicament treatment and poor effectiveness, the invention provides a craniocerebral trauma postoperative injectable hydrogel with the functions of response release and nerve nutrition; the injectable hydrogel after craniocerebral trauma operation can be injected at the position of craniocerebral trauma in situ, and can play the role of early anti-inflammation and trophic nerve by responding to the excessive matrix metalloproteinase and active oxygen in the local microenvironment of the craniocerebral trauma and finally releasing the trophic nerve substance curcumin. The mode of in-situ injection administration can avoid the toxic and side effects of blood viscera of the whole body, improve the local concentration of the medicine in the cerebral trauma, effectively improve the effect of the cerebral trauma treatment in time and improve the level of the treatment of the craniocerebral trauma.
The invention is realized by the following technical scheme, and the craniocerebral trauma postoperative injectable hydrogel with the functions of responding to release and nourishing nerves is characterized in that: the injectable hydrogel after craniocerebral trauma operation at least contains: triglycerol monostearate (TGMS), PPS120OH and curcumin (Cur), wherein the substances are subjected to hydrophilic and hydrophobic self-assembly in a heating mode to form the injectable hydrogel after craniocerebral trauma operation.
The invention relates to an optimized scheme of the craniocerebral trauma postoperative injectable hydrogel with the functions of responding release and nourishing nerves, which comprises the following steps: the injectable hydrogel used after craniocerebral trauma operation is prepared from TGMS and PPS120-OH, Cur species are composed by a hydrophilic-hydrophobic self-assembly form;
wherein the injectable hydrogel after craniocerebral trauma operation has a volume of 1mL and is prepared from 800 μ L, water, 200 μ L, and mixed solvent composed of dimethyl sulfoxide (DMSO), and TGMS (100mg) and PPS120OH, (16mg) and Cur (4mg), heating to 65 ℃ in a water bath, keeping for 5min, and cooling at room temperature to form the injectable hydrogel after craniocerebral trauma surgery.
The invention relates to an optimized scheme of the craniocerebral trauma postoperative injectable hydrogel with the functions of responding release and nourishing nerves, which comprises the following steps: the TGMS has the function of responding to matrix metalloproteinase decomposition in a brain trauma microenvironment, and the structural formula of the TGMS is shown as follows:
the invention relates to an optimized scheme of the craniocerebral trauma postoperative injectable hydrogel with the functions of responding release and nourishing nerves, which comprises the following steps: the PPS120the-OH has the function of responding to active oxygen in brain trauma microenvironment and has the following structural formula:
wherein n is 120.
The invention has the beneficial effects that:
1. the invention relates to a craniocerebral trauma postoperative injectable hydrogel with the functions of response release and nerve nourishment, wherein the used triglycerol monostearate is a substance which is approved by FDA and has an amphiphilic segment, and the hydrogel is safeLeaning on; PPS120-OH is a hydrophobic substance with active oxygen consumption, and curcumin is a traditional Chinese medicine extract with low toxic and side effects on human body.
2. The invention relates to craniocerebral trauma postoperative injectable water condensation with response release and nerve nutrition functions, which can be self-assembled into injectable hydrogel due to the introduction of TGMS, and can wrap PPS (polyphenylene sulfide) due to hydrophilic and hydrophobic effects120-OH and Cur. So that the injection can be performed in situ of craniocerebral trauma.
3. The invention relates to an injectable hydrogel with the functions of responding to release and nourishing nerves after craniocerebral trauma operation, which is caused by TGMS and PPS120The introduction of-OH can in turn respond to matrix metalloproteases, ROS, in the wound environment, thereby accelerating hydrogel cleavage.
4. The invention relates to a craniocerebral trauma postoperative injectable hydrogel with the functions of responding release and nourishing nerves, which comprises PPS120the-OH can consume active oxygen in a brain trauma wound microenvironment to play an anti-inflammatory role, and Cur is released after the hydrogel is cracked to have a nerve nourishing function.
Drawings
FIG. 1 is PPS120of-OH1H-NMR detection results;
FIG. 2 is a PPS120-GPC measurement of OH;
FIG. 3 is a morphological diagram of an injectable hydrogel after craniocerebral trauma surgery prepared by the present invention;
FIG. 4 is the result of HR scanning electron microscope, which shows the surface morphology of injectable hydrogel after craniocerebral trauma operation;
FIG. 5 is a rheological examination of an injectable hydrogel after craniocerebral trauma;
FIG. 6 is the ability of the injectable hydrogel of the invention after TM/PC craniocerebral trauma to release curcumin in different simulated environments in vitro;
FIG. 7 is a graph showing the drug release and degradation of DiR encapsulated in injectable hydrogel after craniocerebral trauma surgery in rats in injury and injury control groups;
FIG. 8 shows the result of a statistical analysis of the fluorescence values of FIG. 7;
FIG. 9 is a diagram showing that the injectable hydrogel after craniocerebral trauma can improve the cerebral edema degree in early craniocerebral trauma;
FIG. 10 shows that the injectable hydrogel of the present invention can improve the blood brain barrier penetration degree after craniocerebral trauma operation;
FIG. 11 shows that the injectable hydrogel of the invention has anti-inflammatory effect after craniocerebral trauma operation;
FIG. 12 the injectable hydrogel after craniocerebral trauma operation of the invention can change the neuron regeneration of craniocerebral trauma.
Detailed Description
The present invention will be further described with reference to the following examples.
Example 1: PPS120Synthesis route and characterization of-OH
PPS120The synthetic route for-OH is shown below: in the synthetic route: the Propylene sulfide is Propylene sulfide and C4H9SH is 1-butanethiol, 2-iodoethanol is 2-iodoethanol, DBU: 1, 8-diazabicyclo [5.4.0]]Undec-7-ene;
propylene sulfide; 1, 8-diazabicyclo [5.4.0] undec-7-ene; 1-butanethiol; 2-iodoethanol was purchased from Taishiai (Shanghai) chemical industry development Co., Ltd.
The preparation method comprises the following steps:
the preparation method of the degassed propylene sulfide comprises the following steps: adding propylene sulfide into a flask, placing the flask on a rotary evaporator, obliquely immersing the flask in about one third of water, and keeping the water temperature at 4 +/-2 ℃; starting a vacuum pump to exhaust air in the device, and starting the condenser and a water inlet valve thereof, wherein the process is carried out for 30 min.
The preparation method of the degassed tetrahydrofuran comprises the following steps: adding tetrahydrofuran into a flask, placing the flask on a rotary evaporator, obliquely immersing the flask in about one third of water, and keeping the water temperature at 4 +/-2 ℃; starting a vacuum pump to exhaust air in the device, and starting the condenser and a water inlet valve thereof, wherein the process is carried out for 30 min.
Adding 1, 8-diazabicyclo [5.4.0] undec-7-ene (258 mg in amount, 1.5mmol) and degassed tetrahydrofuran (1.5 mL) into a round-bottom flask, and degassing at 0 ℃ for 30min to obtain a degassed DBU tetrahydrofuran solution;
dropwise adding 1-butanethiol (45 mg,0.5mmol) into degassed DBU tetrahydrofuran solution, reacting for 30min, and maintaining the temperature at 0 deg.C to obtain reaction system mixture;
degassed propylene sulfide (2.96 g,40mmol) was added to the reaction mixture and reacted at 0 ℃ for 2 hours; adding 2-iodoethanol (172 mg,1mmol), stirring at room temperature for 12 hr, terminating the reaction, filtering the polymer solution to remove precipitated salt, precipitating with cold methanol for three times for further purification, and vacuum drying to obtain colorless viscous polymer, i.e. PPS product120-OH。
PPS120of-OH1The results of H-NMR measurements are shown in FIG. 1; PPS120The GPC measurement of-OH is shown in FIG. 2.
Example 2: the morphological diagram, the high resolution electron microscope examination and the rheological examination of the craniocerebral trauma postoperative injectable hydrogel with the functions of responding to release and nourishing nerves.
Weighing 100mg of TGMS; 16mg PPS120OH and 4mg Cur, respectively dissolved in a mixed solvent of 800. mu.L water and 200. mu.L dimethyl sulfoxide, and heated to 65 deg.C until TGMS and PPS120the-OH and the Cur are uniformly dissolved, and then the solution is cooled at room temperature for 30min to be converted into viscous gel, namely the injectable hydrogel after the craniocerebral trauma operation, as shown in figure 3, the right side II in figure 3 is a liquid bottle which is placed in an inverted mode, the hydrogel does not fall, and the success of preparing the injectable hydrogel after the craniocerebral trauma operation is shown.
The prepared injectable hydrogel after the craniocerebral trauma operation is injected into a small hole of a special sample stage for freezing and transmission by an injector, then is transferred into liquid nitrogen mud for rapid freezing to-210 ℃, and is transferred into a preparation chamber by a transmission rod; adjusting the indoor temperature, increasing the temperature from-140 deg.C to-90 deg.C, sublimating for 3min, and spraying platinum film on the surface of injectable hydrogel after craniocerebral trauma operation for 50 s; the treated injectable hydrogel after craniocerebral trauma surgery was transferred to an HR scanning electron microscope (Zeiss Merlin High resolution SEM) for observation and photographing, and the figure is shown in figure 4.
The samples were tested for dynamic rheological properties using a Discovery HR-2 rotary rheometer manufactured by TA Instruments, USA. The diameter of the parallel plates is 40mm, the plate spacing is 500 μm, and the instrument selects the "oscillatory test" mode during testing. The frequency sweep range was 0.0398-628.319rad/s, strain 5%, temperature 37 ℃, and the storage modulus (G '), loss modulus (G') versus angular frequency (ω) for the sample was obtained, see FIG. 5, where: TM represents TGMS hydrogel group; TM/C represents a TGMS Cur-loaded hydrogel group; TM/P stands for TGMS Encapsulated PPS120-a hydrogel group of OH; TM/PC stands for TGMS Encapsulated PPS120-OH and Cur. From fig. 5, it can be obtained that the injectable hydrogel after craniocerebral trauma operation has hydrogel rheological properties.
Example 3: the craniocerebral trauma postoperative injectable hydrogel with the functions of responding to release and nourishing nerves has the capability of releasing curcumin in different simulated environments in vivo and in vitro.
TM/PC (representing TGMS entrapping PPS) detection by using multifunctional microplate reader120-hydrogel group of OH and Cur, i.e. injectable hydrogel after craniocerebral trauma surgery), Cur release rate in different simulated environments in vitro; taking 200 mu L of craniocerebral trauma postoperative injectable hydrogel, adding 10mL of Phosphate Buffer Saline (PBS), setting different in-vitro environments, adding 10 mu L of different solvents every three days, standing in a 37 ℃ incubator, sampling at different time points, detecting the concentration of Cur in a supernatant by using a multifunctional microplate reader, and calculating the cumulative release amount of the drug, wherein the figure is 6; the results in the figure show that Cur is released most rapidly under the dual action of hydrogen peroxide and matrix metalloproteinase.
Adding 10 mu L of different solvents every three days, wherein the specific names and the concentrations of the different solvents are as follows:
1) PBS denotes: phosphate buffered saline solution;
2)、H2O2represents: hydrogen peroxide (concentration 1 mol/L);
3) MMP-2 represents: matrix metalloproteinase 2 (concentration 100 ng/. mu.L);
4)、H2O2+ MMP-2 represents: hydrogen peroxide (concentrated)Degree 2mol/L) + matrix metalloproteinase 2 (concentration 200 ng/. mu.l), each at a volume ratio of 1: 1, mixing and preparing;
5) MMP-2+ Inhibitor, for: matrix metalloproteinase 2 (concentration 200 ng/. mu.L) + matrix metalloproteinase inhibitor (concentration 2mmol/L), each at a volume ratio of 1: 1, mixing and preparing;
6)、H2O2+ MMP-2+ Inhibitor denotes: hydrogen peroxide (concentration 3mol/L) + matrix metalloproteinase 2 (concentration 300 ng/. mu.l) + matrix metalloproteinase inhibitor (concentration 3mmol/L), each at a volume ratio of 1: 1: 1, mixing and preparing.
The experimental animal is selected from ICR male mice (16-20g), purchased from Beijing Huafukang biotech GmbH, and subjected to animal experiment after being adaptively raised for 12 days in advance. The experimental animals are raised in an independent air supply isolation cage, the room temperature is controlled at 23 +/-2 ℃, regular illumination is kept (12h day and 12h night), and the water and the grain are fully supplied.
The degradation and release capacity of the injectable hydrogel after the craniocerebral trauma in vivo is evaluated by detecting the metabolic intensity of the fluorescent dye in the craniocerebral trauma animal body by using a small animal living body imager and encapsulating the fluorescent dye in the injectable hydrogel after the craniocerebral trauma, and the degradation and release capacity of the injectable hydrogel after the craniocerebral trauma in vivo is shown in figure 7(Sham group is a Sham operation group, TBI is a brain trauma group) and figure 8 (ns: non-statistical value; P: 0.01; P: 0.001).
Example 4 post-craniocerebral trauma injectable hydrogels with responsive release and trophic neurological functions improved the extent of craniocerebral trauma in early animals.
Applying the dry-wet-weight method to the brain and evaluating the effect of the hydrogel on the edema after craniocerebral trauma, as shown in figure 9 (Cont: untreated group of brain trauma; TM/PC is treated group of the hydrogel administered to TM/PC after brain trauma; P: 0.001); using an enzyme-labeling instrument to detect the absorbance of evans blue, and evaluating the protective effect of the hydrogel on the blood brain barrier after craniocerebral trauma, as shown in figure 10 (Cont: a brain trauma untreated group; TM/PC: a treatment group for applying the TM/PC hydrogel to the brain trauma; P: 0.0001); glial Fibrillary Acidic Protein (GFAP) and microglia/macrophage specific protein (Iba-1) were detected by immunofluorescence staining to evaluate the level of neuroinflammation around the cranial lesions, as shown in FIG. 11 (Cont: untreated group of brain wounds; TM/PC: treated group of brain wounds administered with TM/PC hydrogel).
Example 5 post-traumatic craniocerebral injury injectable hydrogel with responsive release and trophic nerve functions can promote the regeneration and repair of neurons after craniocerebral injury.
The expression level of neuron indexes Nestin and neurofilament protein NF-200 around the craniocerebral trauma focus is evaluated by using an immunofluorescence staining method, and is shown in figure 12 (both Nestin and NF-200 are molecular markers for neuron regeneration and repair; Cont is a brain trauma untreated group; and TM/PC is a treatment group for applying the TM/PC hydrogel to the brain trauma).
Claims (1)
1. An injectable hydrogel with functions of responding to release and nourishing nerves after craniocerebral trauma operation, which is characterized in that: the injectable hydrogel after craniocerebral trauma operation at least comprises: triglycerol monostearate, PPS120OH and curcumin, wherein the substances are subjected to hydrophilic and hydrophobic self-assembly in a heating mode to form the craniocerebral trauma postoperative injectable hydrogel;
the injectable hydrogel used after craniocerebral trauma operation is prepared from triglycerol monostearate and PPS120OH, curcumin and a mixed solvent, wherein each substance is added into the mixed solvent and is subjected to hydrophilic-hydrophobic self-assembly by a heating mode;
wherein, the 1ml volume of the injectable hydrogel after craniocerebral trauma operation is a mixed solvent consisting of 800 muL, water, 200 muL and dimethyl sulfoxide, and is added with triglycerol monostearate, 100mg and PPS120Heating OH, 16mg and curcumin, 4mg in water bath to 65 ℃, keeping for 5min, and cooling at room temperature to form craniocerebral trauma postoperative injectable hydrogel;
the triglycerol monostearate has the function of responding to matrix metalloproteinase decomposition in a brain trauma microenvironment, and the structural formula of the triglycerol monostearate is shown as follows:
the PPS120the-OH has the function of responding to active oxygen in brain trauma microenvironment and has the following structural formula:
wherein n is 120.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910274328.5A CN110974777B (en) | 2019-04-08 | 2019-04-08 | An injectable hydrogel after craniocerebral trauma with responsive release and nutritive neural function |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910274328.5A CN110974777B (en) | 2019-04-08 | 2019-04-08 | An injectable hydrogel after craniocerebral trauma with responsive release and nutritive neural function |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110974777A CN110974777A (en) | 2020-04-10 |
| CN110974777B true CN110974777B (en) | 2022-03-18 |
Family
ID=70081668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910274328.5A Active CN110974777B (en) | 2019-04-08 | 2019-04-08 | An injectable hydrogel after craniocerebral trauma with responsive release and nutritive neural function |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110974777B (en) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1756530A (en) * | 2002-12-30 | 2006-04-05 | 血管技术国际股份公司 | Drug delivery from rapid gelling polymer composition |
| WO2010120385A1 (en) * | 2009-04-18 | 2010-10-21 | Massachusetts Institute Of Technology | pH SENSITIVE BIODEGRADABLE POLYMERIC PARTICLES FOR DRUG DELIVERY |
| EP3888632A1 (en) * | 2010-09-24 | 2021-10-06 | The Brigham and Women's Hospital, Inc. | Nanostructured gels capable of controlled release of encapsulated agents |
| KR20150126394A (en) * | 2013-03-06 | 2015-11-11 | 가부시끼가이샤 쓰리디 매트릭스 | Surgical methods employing purified amphiphilic peptide compositions |
| CN107550921B (en) * | 2017-08-24 | 2020-04-14 | 南京邮电大学 | A nanoparticle-polymer injectable composite hydrogel dual drug-loading system and preparation method thereof |
-
2019
- 2019-04-08 CN CN201910274328.5A patent/CN110974777B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN110974777A (en) | 2020-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xu et al. | A multimodal antimicrobial platform based on MXene for treatment of wound infection | |
| Zhang et al. | An injectable dipeptide–fullerene supramolecular hydrogel for photodynamic antibacterial therapy | |
| Chu et al. | Silica-supported near-infrared carbon dots and bicarbonate nanoplatform for triple synergistic sterilization and wound healing promotion therapy | |
| TWI439288B (en) | Medicinal carriers and preparation method and uses thereof | |
| Liu et al. | Magnesium metal–organic framework microneedles loaded with curcumin for accelerating oral ulcer healing | |
| CN106361816A (en) | Wound disinfecting spraying film agent and preparation method thereof | |
| CN114432276A (en) | Bacterial responsive microneedle patch and preparation method and application thereof | |
| Niu et al. | A multi-targeted nanoconjugate for light-driven therapy of chronic wounds | |
| CN113855802A (en) | A biomimetic nano-bait and preparation method thereof and application in the treatment of sepsis | |
| Wu et al. | Enhanced diabetic foot ulcer treatment with a chitosan-based thermosensitive hydrogel loaded self-assembled multi-functional nanoparticles for antibacterial and angiogenic effects | |
| CN114225046A (en) | Antibacterial/healing-promoting dual-drug delivery system, pharmaceutical composition and preparation method and application thereof | |
| CN116139073B (en) | Inflammation targeting hydrogel loaded with antioxidant nano particles and preparation method thereof | |
| Li et al. | Chitosan-based composite film dressings with efficient self-diagnosis and synergistically inflammation resolution for accelerating diabetic wound healing | |
| Noh et al. | Preparation of drug-immobilized anti-adhesion agent using visible light-curable alginate derivative containing furfuryl group | |
| CN110974777B (en) | An injectable hydrogel after craniocerebral trauma with responsive release and nutritive neural function | |
| Guo et al. | α-Amylase and polydopamine@ polypyrrole-based hydrogel microneedles promote wound healing by eliminating bacterial infection | |
| AU2020100021A4 (en) | Hydrogel, pharmaceutical composition comprising same, and application thereof | |
| KR20110124168A (en) | HPOO compound and its preparation method, pharmaceutical composition, drug carrier and imaging agent for the prevention or treatment of inflammatory disease containing the same as an active ingredient | |
| CN112773887A (en) | Temperature-sensitive gel for colonic mucosa repair | |
| Gu et al. | Preparation of a minocycline polymer micelle thermosensitive gel and its application in spinal cord injury | |
| CN113041214A (en) | Modified hyaluronic acid hydrogel loaded with mucinous-Ackermanella tabescens and preparation method and application thereof | |
| CN103705474B (en) | Lyophilized pharmaceutical composition containing omeprazole sodium | |
| Wu et al. | Ropivacaine and celecoxib-loaded injectable composite hydrogel for improved chronic pain-exacerbated myocardial ischemia-reperfusion injury | |
| Li et al. | Cyclodextrin-based self-assembling hydrogel for Photothermal-controlled nitric oxide release in stage-specific treatment of MRSA-induced arthritis | |
| CN113599537A (en) | A kind of nano-aggregate and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |